Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

I-Mab to Develop TJM2 for Cytokine Release Syndrome Patients with COVID-19

americanpharmaceuticalreviewMarch 16, 2020

Tag: I-Mab Biopharma , TJM2 , COVID-19 , cytokine storm

PharmaSources Customer Service